Serum Biomarker Measurements of Endothelial Function and Oxidative Stress After Daily Dosing of Sildenafil in Type 2 Diabetic Men With Erectile Dysfunction

Department of Urology, The James Buchanan Brady Urological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
The Journal of urology (Impact Factor: 4.47). 11/2008; 181(1):245-51. DOI: 10.1016/j.juro.2008.09.005
Source: PubMed


We investigated changes in serum biomarkers of vascular function after short-term, continuous sildenafil dosing in men with type 2 diabetes with erectile dysfunction.
Men with erectile dysfunction associated with type 2 diabetes mellitus were randomized to receive continuous, daily sildenafil (50 mg for 1 week run-in and 100 mg for 3 weeks) (148), or placebo (144) for 4 weeks (phase I) and then sildenafil (25, 50 or 100 mg) on demand for 12 weeks (phase II). Blood draws at baseline and after phases I and II were analyzed for cyclic guanosine monophosphate (endothelial function marker), 8-isoprostane (oxidative stress marker), and interleukin-6 and interleukin-8 (inflammatory cytokines). Primary and secondary erectile function outcome variables were affirmative responses on Sexual Encounter Profile question 3 (ability to maintain erection sufficient for sexual intercourse) and Erection Hardness Score, respectively.
Serum cyclic guanosine monophosphate levels were increased in the sildenafil group relative to the placebo group at 4 (p <0.01) and 16 (p <0.05) weeks, correlating with affirmative responses to Sexual Encounter Profile question 3 at the 4-week interval only (p <0.05). Serum 8-isoprostane levels were decreased to a nonsignificant degree in the sildenafil group at 4 weeks with no further change at 16 weeks, whereas interleukin-6 and interleukin-8 levels were unchanged at either interval, and these levels were unassociated with erectile function outcomes.
These data suggest that short-term, continuous sildenafil treatment causes systemic endothelial function to be enhanced and remain so for a duration after its discontinuation. However, they do not indicate any influence of this treatment on systemic oxidative stress or inflammation, or an effect on long-term erectile function improvement.

Download full-text


Available from: Bruce Trock, Mar 11, 2014
  • Source
    • "The improved endothelial function was maintained for a certain period of time after the discontinuation of daily medication, but EF returned to its pre-treatment status. These findings indicate that the improvement of endothelial cell function by daily administration is not necessarily connected to the improvement of EF.74,75 "
    [Show abstract] [Hide abstract]
    ABSTRACT: In February 2011, the Korean Society for Sexual Medicine and Andrology (KSSMA) realized the necessity of developing a guideline on erectile dysfunction (ED) appropriate for the local context, and established a committee for the development of a guideline on ED. As many international guidelines based on objective evidence are available, the committee decided to adapt these guidelines for local needs instead of developing a new guideline. Considering the extensive research activities on ED in Korea, data with a high level of evidence among those reported by Korean researchers have been collected and included in the guideline development process. The latest KSSMA guideline on ED has been developed for urologists. The KSSMA hopes that this guideline will help urologists in clinical practice.
    08/2013; 31(2):83-102. DOI:10.5534/wjmh.2013.31.2.83
  • Source
    • "The placebo pills were designed by Pfizer and appropriately simulated the look and feel of sildenafil citrate tablets. Study duration was based on published literature showing continuous short-term sildenafil (for 4 weeks) results in the enhancement of systemic endothelial function, with benefits maintained for more than 16 weeks (Burnett et al, 2009). On-demand dosing was not examined in this study because a longer time period would most likely be required to capture the impact on endothelial function—especially given the lack of acute flow-mediated dilation (FMD) response in patients taking on-demand sildenafil (Stirban et al, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Diminished vascular endothelial function results in decreased vasodilator capacity and is associated with erectile dysfunction (ED) in patients afflicted with type 2 diabetes. The current study was designed to evaluate whether daily use of sildenafil could alter endothelial function and improve penile rigidity in a group of patients with diabetic ED. A double-blind, placebo-controlled, prospective trial was conducted with 24 men with type 2 diabetes who were randomized into 2 groups: one receiving daily sildenafil (50 mg, n = 12) and the other placebo (n = 12) for 10 weeks. Erectile function was captured subjectively using the International Index of Erectile Function (IIEF-5), and endothelial function was objectively monitored via brachial artery flow-mediated dilation. Among the placebo and sildenafil groups, there were no significant differences in average patient age, time from type 2 diabetes diagnosis, duration of ED, or baseline IIEF-5 scores. Past medical histories, including smoking, alcohol consumption, hypertension, and hyperlipidemia, were also similar. At the conclusion of the 10-week trial, patients who received daily sildenafil had significantly improved erectile rigidity as captured by IIEF-5 (P < .001) and increased endothelial function via brachial artery flow-mediated dilation (P < .01). Endothelial function in men with type 2 diabetes was enhanced with daily sildenafil. Improved erectile rigidity and enhanced vascular circulation was noted after 10 weeks of daily sildenafil use.
    Journal of Andrology 06/2011; 33(2):176-80. DOI:10.2164/jandrol.111.013367 · 2.47 Impact Factor
  • Source
    • "It has been suggested that oral vasoactive pharmacotherapy, such as PDE5 inhibitor drugs, may provide vasculo‐protective benefits for cardiovascular disease as well as for vasculogenic ED.18 Reduced serum oxidative stress is thought to be the foundation of this mechanism. Moreover, in support of this theory from the opposite side, oxidative stress has been shown to have a role in the development and progression of atherosclerosis.19 "
    [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the acute effect of phosphodiesterase type 5 (PDE5) inhibitor on erectile dysfunction by evaluating serum oxidative status and prolidase activity. Serum samples of 36 patients with erectile dysfunction and 30 control cases were analyzed for total antioxidant status, total oxidant status, and prolidase activity, before and after the administration of tadalafil citrate. Before and after tadalafil citrate administration, serum total antioxidant status, total oxidant status, and prolidase were 1.1+0.0 vs. 1.6 + 0.0 umol H₂O₂ Eq/L, 10.3+1.1 vs. 6.9 + 1.2 umol H₂O₂ Eq/L, and 236.4+19.5 vs. 228.2 + 19.2 U/L, respectively (p < 0.0001 for all). Evaluation of serum oxidative status and prolidase activity confirmed the beneficial acute effects of PDE5 inhibitor in patients with erectile dysfunction.
    Clinics (São Paulo, Brazil) 12/2010; 65(12):1311-4. DOI:10.1590/S1807-59322010001200014 · 1.19 Impact Factor
Show more